QT Imaging Exceeds 2025 Revenue, Forecasts Double 2026 Growth, Secures Critical CPT Code
QTI has more than doubled off its 52-week low of $0.523.
Summary
QT Imaging Holdings reported strong fourth quarter and full-year 2025 financial results, exceeding its revenue outlook with $18.9 million for the year and providing robust 2026 revenue guidance of $39 million, more than double the prior year. This positive financial performance is bolstered by several significant strategic and regulatory achievements, including the American Medical Association's approval of a new Category III CPT code for its Breast Acoustic CT scanner, which is crucial for future reimbursement and broader clinical adoption. The company also secured U.S. FDA 510(k) clearance for an updated scanner configuration, uplisted to The Nasdaq Capital Market, and strengthened its balance sheet with an $18.2 million private placement. Strategic collaborations with Intelerad Medical Systems and Olea Medical, alongside an exclusive UAE distribution agreement, further position QTI for growth as it transitions to a SaaS- and biomarker-driven medical imaging platform. Traders will be watching for continued execution on the ambitious 2026 guidance and the successful integration and adoption of the new CPT code.
At the time of this announcement, QTI was trading at $6.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.2M. The 52-week trading range was $0.52 to $8.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.